Articles tagged with Rheumatoid Arthritis
A new protein (C5orf30) has been identified as a genetic marker that can help regulate the severity of tissue damage caused by rheumatoid arthritis. This discovery enables early identification of patients at risk of severe joint damage, allowing for fast-tracked treatment with more aggressive therapies.
A new protein (C5orf30) has been identified as a genetic marker for rheumatoid arthritis severity, allowing for early diagnosis and targeted treatment. This breakthrough discovery has the potential to improve patient outcomes and reduce tissue damage caused by the condition.
Research reveals that depressive symptoms, stress, anxiety, and anger are associated with increased atherosclerosis markers in RA patients. Screening and treatment of psychosocial symptoms may curb the cardiovascular disease burden in this patient group.
Researchers link positive and negative mood to daily pain in rheumatoid arthritis patients, suggesting that interventions targeting depression and momentary mood may improve pain and quality of life. The study's findings may have implications for individuals with chronic pain beyond rheumatoid arthritis.
A metagenome-wide association study uncovered markers in the oral and gut microbiomes that are associated with rheumatoid arthritis (RA). The study found that Haemophilus sp. is depleted in RA patients and Lactobacillus salivarius is over-represented, suggesting potential new targets for diagnosis and treatment.
Researchers found that total knee replacement reduces knee pain and improves subjective quality of life indices in rheumatoid arthritis patients. However, improvements were not as great as those experienced by osteoarthritis patients.
A study has identified a potential link between inflammation caused by rheumatoid arthritis and the development of heart valve disease, including aneurysms. The research team hopes that existing medicines that dampen inflammation could be repurposed to treat heart valve diseases.
A new study found that a test can predict which rheumatoid arthritis patients will fail to respond to biologic drugs. Detecting low drug levels and anti-drug antibodies in the bloodstream can help adjust treatments.
Studies found increased incidents of rheumatoid arthritis and giant cell arteritis in concert with the cycle of magnetic activity of the sun. Correlations were strongest between diseases and geomagnetic activity, with GCA incidence peaking within one year of intense geomagnetic activity.
A dose reduction strategy for TNF inhibitors can maintain good clinical response in RA patients even when the dose is reduced by one-third. Reducing the dose by two-thirds results in more flares, but these subsided when the higher dose was restarted.
Early RA patients exhibit cardiomyopathy, reduced vascular function, and increased cardiovascular mortality. Cardiac MRI revealed aortic stiffness, left ventricular volumes, and geometry changes indicative of cardiac abnormalities.
A systematic review of 15 randomized controlled trials found that biologics significantly reduce accumulated missed workdays and improve work productivity among patients with rheumatic diseases. This suggests a potential economic benefit to treating these conditions.
Two studies show ultrasound can identify RA patients in clinical remission with active subclinical synovitis, highlighting the risk of progressive joint damage. High-resolution ultrasound diagnoses active subclinical synovitis identifies patients who benefit from more intensive treatment.
A study found that people with rheumatoid arthritis are less protected by the hepatitis B vaccine, highlighting increased risk of infection despite vaccination. The vaccine's efficacy was lower in RA patients compared to those without the condition.
Fatigue remains a debilitating problem for RA patients, with healthcare professionals often failing to measure it. New guidelines recommend validated fatigue measurements to improve patient outcomes. In contrast, treatment aimed at achieving disease remission is unlikely to be effective in addressing fatigue.
A study found that RA patients with moderate disease activity are at risk of needing joint surgery, challenging existing treatment guidelines. The findings suggest updating disease activity cut-off points to allow moderate-disease-activity patients to receive biologics.
The tREACH trial found that combination DMARDs (methotrexate, sulfasalazine, and hydroxychloroquine) improve measures of disease activity and functional ability in patients with early rheumatoid arthritis. This suggests an earlier decrease in disease severity and improvements in functional ability compared to monotherapy.
A study presented at EULAR 2015 found that ultrasound diagnosis of tenosynovitis was superior to clinical symptoms in predicting early RA. This procedure has the potential to improve clinical outcomes by identifying the need for treatment before symptom onset.
A world-first vaccine-style therapeutic approach has demonstrated safety and effectiveness in suppressing the immune response in a phase one clinical trial for rheumatoid arthritis. The treatment targets high-risk genes and antibodies associated with the disease.,
A recent UK study found that 40% of rheumatoid arthritis patients scored low on an adherence questionnaire, indicating inconsistent medication use. The research highlights the need for healthcare professionals to better inform patients about the importance of taking drugs as prescribed.
A team of researchers from Montana State University has identified a new chemical compound called IQ-1S that shows promise in treating rheumatoid arthritis. The study found that IQ-1S significantly reduced the severity of collagen-induced arthritis and inhibited the destruction of cartilage and bone.
A new class of medications could prevent joint damage and provide relief to patients who don't respond to available treatments. The novel drug target, RPTPσ, inhibits the aggressive invasion of synoviocytes into joint cartilage by acting as an inhibitory signal.
Research suggests that 1 in 4 patients with rheumatoid arthritis and no symptoms have coronary heart disease, increasing their risk of cardiovascular death. The study found that persistence of systemic inflammation may cause accelerated atherosclerosis process in rheumatoid arthritis patients.
Patients with rheumatoid arthritis who experience weight loss are at higher risk of early death. The study's findings suggest a potential link between unintentional weight loss and mortality in this patient population.
A new study has discovered specific genetic variants associated with higher risks of increased disease severity in rheumatoid arthritis. Certain amino acid positions in the HLA-DRB1 gene were found to be strong predictors of radiological damage, enabling early identification and potential treatment optimization.
A recent study found that patients with rheumatoid arthritis face high initial copayments and then fall into a coverage gap, where they pay 45% of drug costs. This financial burden can be substantial, with some patients paying over $2,700 annually before receiving relief from catastrophic coverage.
A team from the University of Birmingham identified a novel pathway regulating immune cell movement during inflammation. The study shows that beneficial effects are lost in diseases such as diabetes and arthritis, and during normal aging. This discovery may lead to new therapies targeting this pathway.
Researchers at the University of Warwick have identified a biomarker linked to both rheumatoid and osteoarthritis, potentially leading to an early diagnosis of OA and RA. The development of a blood test using this biomarker could help patients receive treatment several years before physical symptoms appear.
Researchers found increased pocket depth and clinical attachment loss in patients with rheumatoid arthritis, highlighting the link between gum disease and joint inflammation. The study also identified Porphyromonas gingivalis antibodies as biomarkers for identifying patients who may benefit from periodontal treatment.
A study led by Tokyo Medical University researcher Toshihiro Nakajima found that an anti-inflammatory drug can counteract obesity in mice by regulating mitochondrial biogenesis and fatty acid breakdown. The drug, LS-102, inhibits the Synoviolin gene, leading to increased energy control pathways.
Researchers identified super-enhancers in T cells as key to regulating the immune system, which may lead to new treatments for autoimmune disorders such as rheumatoid arthritis. The study found that these enhancers control genes involved in T cell function and activity.
A study of almost 6500 people found that recent gut and urinary tract infections were associated with a significantly lowered risk of developing rheumatoid arthritis. Infections within the past two years reduced the risk by 29%, 22% and 20% respectively.
Researchers found that blood tests can produce similar results for patients with Chikungunya virus and those with rheumatoid arthritis, highlighting the need for diagnostic tools. Detailed travel histories are crucial to distinguish between the two conditions.
New clinical data show Vectra DA is a strong predictor of radiographic progression over two years compared to other tests used to assess risk of joint damage. The study found that among patients with low CRP, high Vectra DA scores were associated with increased risk of radiographic progression.
A study at Hospital for Special Surgery found that a support group addressing the psychological and educational needs of people recently diagnosed with rheumatoid arthritis has a strong positive impact on their lives. The program improved patients' ability to manage their disease, connect with others, and cope with emotional challenges.
Researchers found that patients with underweight or overweight/obese BMIs were less likely to achieve sustained remission in early rheumatoid arthritis. The study also identified other contributing factors, such as smoking and response to treatment, that can impact patient outcomes.
A blood test shows promise as a marker to predict which rheumatoid arthritis patients will benefit from biologic medications, sparing them unnecessary side effects. The protein type 1 interferon appears to serve as a valid marker to tell whether individual patients will respond to biologics or need alternative treatments.
Research found that babies born to mothers with rheumatoid arthritis have lower fetal growth and are more likely to be born prematurely. Studies show a 1.5 times higher risk of preterm birth in children exposed to maternal or preclinical RA compared to those without exposure.
A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects. The COBRA Slim strategy, which calls for the least amount of medication, had half as many side effects as the two other strategies and was just as effective.
Crescendo Bioscience will showcase new clinical data on Vectra DA at the 2014 ACR Annual Meeting, highlighting its value in assessing RA disease activity and predicting patient risk of joint damage. The company will present two oral presentations and four poster presentations.
Researchers at Hospital for Special Surgery have discovered a novel cell signaling pathway contributing to bone destruction in rheumatoid arthritis. The study suggests that RBP-J protein controls excessive bone erosion through a newly identified signaling pathway.
Researchers found that women with children carrying high-risk HLA genes are more likely to develop rheumatoid arthritis. The study suggests a possible link between fetal microchimerism and the disease, which may be mediated by interactions between immune system proteins encoded by these genes.
The National Institutes of Health has established an Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network to transform the current model for identifying promising biological targets for new drugs and diagnostics. The network will analyze interplay among biological pathways, including at the single...
Researchers found cartilage plays an active role in rheumatoid arthritis destruction and remodelling, contradicting the long-held assumption that it's a passive victim of inflammation. Cartilage produces enzymes driving tissue degradation and releases signaling molecules triggering an autoimmune response.
A team of researchers at the University of Illinois Chicago has identified a single receptor, TLR5, that triggers inflammation and bone degradation in rheumatoid arthritis. Blocking this receptor may provide a new therapeutic target to interrupt the disease's vicious cycle.
A new study found that high sodium intake in smokers doubles the risk of developing rheumatoid arthritis. The study suggests an additive interaction between sodium and smoking as a risk factor for RA.
A new study found that 27% of rheumatoid arthritis patients in the UK failed to take their expensive anti-TNF therapy as prescribed. Non-adherence to medication reduced its effectiveness and worsened disease outcomes, highlighting a significant concern for healthcare resources.
A study by Wayne State University researchers found that cognitive-behavioral coping skills training significantly improved RA patients' pain and mood for at least a year. In contrast, written emotional disclosure had only short-term benefits on joints and functioning. The combination of both therapies showed no unique benefits.
A new fusion molecule has been developed to treat rheumatoid arthritis in mice, with promising results showing the animals' symptoms disappear completely. The therapy targets specific immune messengers and reduces side effects by concentrating the active substance at the site of disease, offering a potential long-term cure.
Rheumatoid arthritis is considered a syndrome rather than a single disease, and blocking inflammasomes may be an effective therapeutic target. Researchers have developed a mouse model that demonstrates the role of inflammasomes in RA and show promise for new treatments.
Amino acids at positions 11, 71 and 74 on the HLA-DRB1 gene identify RA patients at risk of joint damage and early death. The findings suggest that genotyping can predict disease outcomes in rheumatoid arthritis patients.
Researchers have identified a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis (RA) through DNA methylation analysis. The study found that epigenetic changes, such as DNA methylation, may provide potential biomarkers of response to anti-TNFs.
A recent EULAR study found that obese patients with rheumatoid arthritis (RA) have higher disease activity scores than non-obese patients, irrespective of their disease stage. This suggests that treatment to target protocols may result in obese patients being treated more aggressively than non-obese patients.
Researchers at Benaroya Research Institute used cutting-edge tetramer technology to find T cells driving rheumatoid arthritis. The study demonstrates that these cells have unique markers and change over time in patients with RA.
New studies have found that daily intake of monounsaturated fatty acids is an independent predictor of remission in patients with RA, while excessive cholesterol levels increase cartilage damage in OA. The Mediterranean diet has been shown to reduce inflammatory activity and improve function in RA patients.
Vectra DA data demonstrates clinical utility in assessing risk of future joint damage, with high scores associated with radiographic progression. The test may help identify patients at higher or lower risks for radiographic progression while receiving antirheumatic therapy.
An international team created a heart disease risk calculator for rheumatoid arthritis patients, identifying those at high risk more effectively than standard tools. The calculator incorporates disease characteristics into cardiovascular risk assessment, shedding light on how to better gauge heart health in inflammatory diseases.
Researchers discovered that CCL28 and its receptor are key players in angiogenesis, a hallmark of rheumatoid arthritis. This finding provides strong evidence for the binding of CCL28 to joint-lining cells as necessary for blood vessel formation.
Researchers from Scripps Research Institute will develop new technology to diagnose three diseases using a unique group of enzymes known as protein arginine deiminases (PAD). PADs have been linked to inflammatory diseases like rheumatoid arthritis, cancer, and Alzheimer's disease.
A traditional Chinese herbal remedy, Tripterygium wilfordii Hook F, has been shown to be as effective as methotrexate in treating rheumatoid arthritis. Combining the herbal remedy with methotrexate resulted in improved outcomes for patients, including significant reductions in disease activity and remission rates.